Phát triển mô hình tế bào để nghiên cứu tín hiệu CCR8 trong tế bào T điều hòa xâm nhập khối u

Plitas G, Konopacki C, Wu K et al (2016) Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45(5):1122–1134

De Simone M, Arrigoni A, Rossetti G et al (2016) Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45(5):1135–1147

Van Damme H, Dombrecht B, Kiss M et al (2021) Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. J Immunother Cancer 9(2):e001749

Campbell JR, McDonald BR, Mesko PB et al (2021) Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models. Cancer Res 81(11):2983–2994

Kidani Y, Nogami W, Yasumizu Y et al (2022) CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proc Natl Acad Sci USA 119(7):e2114282119

Weaver JD, Stack EC, Buggé JA et al (2022) Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology 11(1):2141007

Whiteside SK, Grant FM, Gyori DS et al (2021) CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function. Immunology 163(4):512–520

Wu Y, Xi J, Li Y et al (2023) Discovery of a potent and selective CCR8 small molecular antagonist IPG7236 for the treatment of cancer. J Med Chem 66(7):4548–4564

Zhang Z, Wang G, Shao X et al (2023) A novel prognostic biomarker CCR8 for gastric cancer and anti-CCR8 blockade attenuate the immunosuppressive capacity of Tregs In Vitro. Cancer Biother Radiopharm. https://doi.org/10.1089/cbr.2022.0095

Liu L, Doijen J, D’huys T et al (2021) Biological characterization of ligands targeting the human CC chemokine receptor 8 (CCR8) reveals the biased signaling properties of small molecule agonists. Biochem Pharmacol 188:114565

Putnam AL, Brusko TM, Lee MR et al (2009) Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58(3):652–662

Revenko A, Carnevalli LS, Sinclair C et al (2022) Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. J Immunother Cancer 10(4):e003892

Zorn E, Nelson EA, Mohseni M et al (2006) IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108(5):1571–1579

McCully ML, Collins PJ, Hughes TR et al (2015) Skin metabolites define a new paradigm in the localization of skin tropic memory T Cells. J Immunol 195(1):96–104

Fraga M, Yáñez M, Sherman M et al (2021) Immunomodulation of T helper cells by tumor microenvironment in oral cancer is associated with CCR8 expression and rapid membrane vitamin D signaling pathway. Front Immunol. https://doi.org/10.3389/fimmu.2021.643298

Mijnheer G, Lutter L, Mokry M et al (2021) Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation. Nat Commun 12(1):2710

Magnuson AM, Kiner E, Ergun A et al (2018) Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. Proc Natl Acad Sci 115(45):E10672–E10681

Miller MD, Hata S, De Waal MR et al (1989) A novel polypeptide secreted by activated human T lymphocytes. J Immunol (Baltim Md 1950) 143(9):2907–2916

Jenkins TJ, Guan B, Dai M et al (2007) Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem 50(3):566–584

Sarkar T, Dhar S, Chakraborty D et al (2022) FOXP3/HAT1 axis controls treg infiltration in the tumor microenvironment by inducing CCR4 expression in breast cancer. Front Immunol. https://doi.org/10.3389/fimmu.2022.740588

Wang L, Simons DL, Lu X et al (2019) Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat Immunol 20(9):1220–1230

Sugiyama D, Nishikawa H, Maeda Y et al (2013) Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci 110(44):17945–17950

Barsheshet Y, Wildbaum G, Levy E et al (2017) CCR8+FOXp3+ Treg cells as master drivers of immune regulation. Proc Natl Acad Sci 114(23):6086–6091

Knipfer L, Schulz-Kuhnt A, Kindermann M et al (2019) A CCL1/CCR8-dependent feed-forward mechanism drives ILC2 functions in type 2–mediated inflammation. J Exp Med 216(12):2763–2777

Giustiniani J, Dobos G, Moins-Teisserenc H et al (2022) CCR8 is a new therapeutic target in cutaneous T-cell lymphomas. Blood Adv 6(11):3507–3512

Louahed J, Struyf S, Demoulin JB et al (2003) CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Eur J Immunol 33(2):494–501

Coghill JM, Fowler KA, West ML et al (2013) CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. Blood 122(5):825–836

Spinetti G, Bernardini G, Camarda G et al (2003) The chemokine receptor CCR8 mediates rescue from dexamethasone-induced apoptosis via an ERK-dependent pathway. J Leukoc Biol 73(1):201–207

Cao M, Cabrera R, Xu Y et al (2007) Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells. Lab Invest 87(6):582–590

Finetti F, Travelli C, Ercoli J et al (2020) Prostaglandin E2 and cancer: insight into tumor progression and immunity. Biology 9(12):434

Takahashi T, Kuniyasu Y, Toda M et al (1998) Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10(12):1969–1980

de la Rosa M, Rutz S, Dorninger H et al (2004) Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 34(9):2480–2488

Moon BI, Kim TH, Seoh JY (2015) Functional modulation of regulatory T cells by IL-2. PLoS One 10(11):e0141864

Kohli K, Pillarisetty VG, Kim TS (2022) Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther 29(1):10–21

Anz D, Rapp M, Eiber S et al (2015) Suppression of intratumoral CCL22 by type I interferon inhibits migration of regulatory T cells and blocks cancer progression. Cancer Res 75(21):4483–4493

Wiedemann GM, Knott MML, Vetter VK, et al. (2016) Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells. Oncoimmunology [Internet]. [cited 2023 Oct 20];5(9). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048775/